These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18767041)

  • 21. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
    Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ; Hernandez-McClain J; Henary H
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Peptide-based cancer vaccine therapy for prostate cancer, bladder cancer, and malignant glioma].
    Yamada A
    Nihon Rinsho; 2011 Sep; 69(9):1657-61. PubMed ID: 21922770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
    BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination.
    Kaufman HL; Divgi CR
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6757-62. PubMed ID: 16203760
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer.
    Uemura H; Fujimoto K; Mine T; Uejima S; de Velasco MA; Hirao Y; Komatsu N; Yamada A; Itoh K
    Cancer Sci; 2010 Mar; 101(3):601-8. PubMed ID: 20128819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
    Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
    Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
    Victora GD; Socorro-Silva A; Volsi EC; Abdallah K; Lima FD; Smith RB; Moyses RA; Zárate-Bladés CR; Michaluart P; Silva CL; Kalil J; Coelho V
    Cancer Gene Ther; 2009 Jul; 16(7):598-608. PubMed ID: 19197326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease].
    Ma CG; Ye DW; Li CL; Zhou FJ; Yao XD; Zhang SL; Dai B; Zhang HL; Zhu Y; Shen YJ
    Zhonghua Wai Ke Za Zhi; 2008 Jun; 46(12):921-5. PubMed ID: 19035151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
    Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
    J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multipeptide vaccination in cancer patients.
    Pilla L; Rivoltini L; Patuzzo R; Marrari A; Valdagni R; Parmiani G
    Expert Opin Biol Ther; 2009 Aug; 9(8):1043-55. PubMed ID: 19591629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up after triple treatment of prostate cancer stage pT3.
    Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
    Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.
    Mennuni C; Ugel S; Mori F; Cipriani B; Iezzi M; Pannellini T; Lazzaro D; Ciliberto G; La Monica N; Zanovello P; Bronte V; Scarselli E
    Cancer Res; 2008 Dec; 68(23):9865-74. PubMed ID: 19047167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
    Bao L; Lu XJ; Zhang XH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Dexamethasone therapy for castration-resistant prostate cancer].
    Nishimura K
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():507-10. PubMed ID: 22208034
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.